Enterococcus gallinarum Flagellin Polypeptides for TLR5 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diseases lack effective characterization of gut bacteria, leading to inadequate development of new therapies, and existing flagellin from species like Salmonella typhimurium have limited understanding and application, particularly for diseases like cancer.
Innovation Solution
Development of flagellin polypeptides from Enterococcus gallinarum, specifically the strain MRx0518, which strongly activates TLR5 responses, is used to treat and prevent cancer, with compositions including monomeric flagellin polypeptides and bacterial flagellar assemblies, and potential use in immunotherapy and vaccine adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If flagellin from Salmonella typhimurium is used to activate TLR5 responses, then immune system activation is achieved, but the therapeutic effectiveness is limited due to poor characterization and understanding
Solution Approach 1:
The patent changes the species parameter from Salmonella typhimurium to Enterococcus gallinarum, and further optimizes to specific strains (MRx0518, NCIMB 42488) with defined genetic sequences. This parameter change resolves the contradiction by providing well-characterized flagellin polypeptides with confirmed TLR5 activation capability, eliminating the information loss associated with poorly characterized Salmonella flagellin
Solution Approach 2:
The patent replaces the mechanical/biological system of using whole Salmonella bacteria with purified recombinant flagellin polypeptides. This substitution provides precise characterization of the active component (flagellin sequence), enabling reliable therapeutic use while eliminating variability associated with whole organism systems
2Loss of time
If new therapies are developed without effective characterization of gut bacteria, then development time is reduced, but therapeutic efficacy is inadequate
Solution Approach 1:
The patent performs preliminary characterization of Enterococcus gallinarum flagellin polypeptides, including sequence determination, TLR5 activation testing, and structural analysis, before clinical application. This preliminary action ensures therapeutic efficacy is established in advance, resolving the contradiction by showing that proper characterization can be completed efficiently without compromising future therapeutic success
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The flagellin polypeptides from Enterococcus gallinarum effectively stimulate a strong TLR5 response, demonstrating potential in treating and preventing cancer, and may have broader applications in immune system stimulation and disease prevention.
Implementation Method 1
The mechanism by which SFB influences T cell responses is currently unknown, but recent genome studies confirming the presence of flagellin genes suggest that innate responses mediated through TLR5-flagellin interactions may play a role
Data Source
AI summary
The invention provides compositions comprising flagellin polypeptides from bacterial strains and the use of such compositions in the treatment of disease.